[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336865-105":59,"doc-detail-336865-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","molecular-targets-for-the-diagnosis-and-treatment-of-pancreatic-cancer","Molecular Targets for the Diagnosis and Treatment of Pancreatic Cancer","","Pancreatic cancer is among the most aggressive malignancies, with five-year survival under 10% and consistently poor prognosis despite advances in treatment. Progress in molecular research has clarified mechanisms driving pancreatic cancer development and progression, enabling identification of diagnostic biomarkers and therapeutic targets. This review synthesizes current knowledge on molecular targets for early diagnosis and targeted therapy, emphasizing key signaling pathways and strategies that could improve detection, survival, and prevention while addressing major barriers to effective treatment.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/molecular-targets-for-the-diagnosis-and-treatment-of-pancreatic-cancer/336865/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/molecular-targets-for-the-diagnosis-and-treatment-of-pancreatic-cancer/336865.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is early diagnosis of pancreatic cancer difficult?","Question",{"text":112,"@type":113},"Most patients show no clear symptoms during disease development, and early detection remains challenging. Existing tumor markers also lack specificity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What major obstacles hinder treatment success?",{"text":117,"@type":113},"At diagnosis, pancreatic cancer is often already metastasized with limited options. The disease’s aggressive biology, extensive mutation burden, and resistance to chemotherapy and radiation reduce effectiveness.",{"name":119,"@type":110,"acceptedAnswer":120},"Which molecular aspects does the review focus on for diagnosis and therapy?",{"text":121,"@type":113},"The review summarizes current molecular targets linked to early diagnosis and targeted treatment, highlighting key signaling pathways and therapeutic strategies, including biomarkers and potential novel intervention targets.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336865,1790600711,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Review  \nMolecular Targets for the Diagnosis and Treatment of Pancreatic Cancer  \nRobert G. Pergolizzi 1 and Steven T. Brower 2, *  \nCitation: Pergolizzi, R.G.; Brower, S.T. Molecular Targets for the Diagnosis and Treatment of Pancreatic Cancer. Int. J. Mol. Sci. 2024, 25, 10843 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms251910843  \nAcademic Editor: Asfar S. Azmi  \nReceived: 7 August 2024  \nRevised: 1 October 2024  \nAccepted: 7 October 2024  \nPublished: 9 October 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Vascular Surgery, Englewood Health, Englewood, NJ 07631, USA; [robert.pergolizzi@ehmchealth.org](robert.pergolizzi@ehmchealth.org)  \n2 Department of Surgical Oncology and HPB Surgery, Englewood Health, Englewood, NJ 07631, USA  \n* Correspondence: [steven.brower@ehmchealth.org](steven.brower@ehmchealth.org)  \nAbstract: Pancreatic cancer is one of the most aggressive and lethal forms of cancer, with a five-year survival rate of less than 10% . Despite advances in treatment modalities, the prognosis for pancreatic cancer patients remains poor, highlighting the urgent need for innovative approaches for early diagnosis and targeted therapies. In recent years, there has been significant progress in understanding the molecular mechanisms underlying pancreatic cancer development and progression. This paper reviews the current knowledge of molecular targets for the diagnosis and treatment of pancreatic cancer.  \nKeywords: PC (pancreatic cancer); driver mutations; miRNA  \n1. Introduction  \nPancreatic cancer (PC) is the seventh leading cause of cancer-related deaths worldwide, with an estimated 495,773 new cases and 466,003 deaths in 2020 [1] . In recent years, the incidence of PC has risen. It accounts for about 2% of all cancers and is responsible for 5% of cancer-related deaths [2] . Most patients exhibit no clear symptoms during the disease’s development, progressing to advanced metastatic stages where tumor cells become highly invasive. Early diagnosis is challenging [2,3], making PC one of the deadliest malignant tumors. The high mortality rate is attributed to the aggressive nature of the disease, latestage diagnosis, and limited treatment options. Despite potential radical treatments, the 5-year survival rate for patients is only 2–9%, with most eventually relapsing [4] . Pancreatic ductal adenocarcinoma (PDAC) is the most common type of PC [2] .  \nRisk factors include family history, pancreatitis, age, sex, diabetes, and a variety of other factors that have been implicated in the etiology of PC to varying degrees. However, there are currently no global standard screening programs for high-risk individuals. To improve prognosis, recent advancements in the risk factors, diagnosis, and treatment of PC have been reviewed elsewhere [5,6] .  \nOver the past few years, the incidence of PC has increased. Most cases are diagnosed at an advanced stage when surgical resection is often not feasible, and current therapies, such as chemotherapy and radiation therapy, offer limited benefit. The early detection of PC is critical for improving outcomes. This paper reviews the current knowledge of molecular targets for the diagnosis and treatment of pancreatic cancer, with a focus on key signaling pathways and therapeutic strategies that may be employed to improve early diagnosis of PC, improve survival, and suggest possible novel targets for intervention and prevention.  \nPC has been the subject of much research and many attempts to improve outcomes. However, the following issues remain major stumbling blocks to the diagnosis and treatment of PC: (a) At the point of di","cbCaik2sY7lNoBAR","https://ap.wps.com/l/cbCaik2sY7lNoBAR","pdf",613842,14,"English","# Introduction\n## Risk factors for pancreatic cancer\n# Molecular targets and challenges in diagnosis and treatment\n## Therapeutic resistance and tumor heterogeneity","[{\"question\":\"Why is early diagnosis of pancreatic cancer difficult?\",\"answer\":\"Most patients show no clear symptoms during disease development, and early detection remains challenging. Existing tumor markers also lack specificity.\"},{\"question\":\"What major obstacles hinder treatment success?\",\"answer\":\"At diagnosis, pancreatic cancer is often already metastasized with limited options. The disease’s aggressive biology, extensive mutation burden, and resistance to chemotherapy and radiation reduce effectiveness.\"},{\"question\":\"Which molecular aspects does the review focus on for diagnosis and therapy?\",\"answer\":\"The review summarizes current molecular targets linked to early diagnosis and targeted treatment, highlighting key signaling pathways and therapeutic strategies, including biomarkers and potential novel intervention targets.\"}]","Molecular Targets for the Diagnosis and Treatment of Pancreatic Cancer | PDF",1790016906,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34916549c02405b46fc498642b4ebf90.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/32c78fde64cbc74b4058f925db29888e.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7315904f2e93150ee9badd281b0ce01.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e258fffae46d0be57f108e7ffa01175.webp",980,1385]